Target intelligence / Profile preview

Immune cell surface antigen

Molecular classification
Receptor, Cell adhesion molecule, Transporter, Enzyme, Other (signal transduction protein, antigen), Glycoproteins, Membrane proteins
01

Overview

Immune cell surface antigens are molecular markers located on the exterior membranes of immune cells, such as lymphocytes (T cells, B cells, NK cells), monocytes, macrophages, dendritic cells, and granulocytes. These molecules determine the phenotypic identity and function of the cells by participating in differentiation, activation, signaling, and cell-to-cell interactions. Commonly characterized as “CD” markers (Cluster of Differentiation numbers, e.g., CD4, CD8, CD20), these antigens allow for the classification and study of immune cell subsets and are widely used as tools for flow cytometry, immunohistochemistry, and targeted therapy. Many surface antigens are directly targeted by modern immunotherapeutics, making them highly relevant for research, diagnostics, and treatment across cancer, autoimmune, infectious, and inflammatory diseases.

Other names
Surface immunological markersdifferentiation antigensCD antigens (Cluster of Differentiation)cell surface markersimmune cell markers
02

Mechanism of action

Mechanisms include immune cell depletion (e.g., antibody-dependent cell-mediated cytotoxicity), immune cell activation or inhibition (agonism or antagonism of receptor/marker), immunomodulation (alteration of signaling pathways), and cell lysis (complement-dependent cytotoxicity). The specific mechanism depends on the individual surface antigen targeted.

03

Biological functions

Cell differentiationCell activationCell signalingAntigen presentationImmune recognitionImmune response regulationCell migrationImmune surveillanceApoptosis
04

Disease associations

Cancer (e.g., tumor markers, immunotherapy targets)Inflammation (autoimmune and inflammatory diseases)Infection (e.g., viral or bacterial recognition)Immunodeficiency (e.g., abnormal marker expression)Transplant rejectionAllergy
05

Safety considerations

Off-target cell depletion (e.g., B cell or T cell aplasia)Cytokine release syndrome (especially with cell-based therapies)Immunosuppression and infection riskAllergic/hypersensitivity reactionsTumor escape (loss or modulation of antigen expression)
06

Interacting drugs

Antibodies (monoclonal antibodies like rituximab, alemtuzumab—target CD20, CD52, etc.)

3 more in the full profile.

07

Biomarkers

CD3 (T cell identification)CD4, CD8 (T cell subset monitoring)CD19, CD20 (B cell identification and therapy monitoring)CD56, CD16 (NK cell monitoring)

Beyond the preview

Go deeper on Immune cell surface antigen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immune cell surface antigen.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call